In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019
Blood Cancer J
.
2019 Nov 19;9(12):89.
doi: 10.1038/s41408-019-0250-4.
Authors
Zandra Klippel
1
,
Amy Kimball
2
,
Christina Tekle
2
Affiliations
1
Amgen, Inc., Thousand Oaks, CA, USA.
[email protected]
.
2
Amgen, Inc., Thousand Oaks, CA, USA.
PMID:
31745070
PMCID:
PMC6863861
DOI:
10.1038/s41408-019-0250-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Bortezomib
Humans
Lenalidomide
Multiple Myeloma*
Thalidomide
Substances
Thalidomide
Bortezomib
Lenalidomide